• multiple myeloma - 2nd line (L2) 1
• myofibroblastic tumors
• neurofibroma
• neutropenia
• osteosarcoma
• ovarian cancer (OC) 9

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus pomalidomide and dexamethasone

• versus all
• vs Immunosuppressant
• vs pomalidomide based treatment
• vs pomalidomide and dexamethasone

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

multiple myeloma - 2nd line (L2), pembrolizumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;